ICHNO-ECHNO 2022 - Abstract Book

S103

ICHNO-ECHNO 2022

Table 1

Conclusion Our study confirms that assessment of nutritional status by BMI is potentially insufficient since BMI variations could hide muscle mass variations that have an impact in HNSCC prognosis. SMI could represent a more reliable way in muscle mass analysis that could be easily integrated in oncological setting. An increase in the sample number would allow a significant assessment of the impact of nutritional supplementation on progression free survival, that nowadays is not well represented in current literature, which focuses more on treatment compliance, RT-CHT toxicity and quality of life.

PO-0164 Dose correlation of Submandibular gland with xerostomia in laryngopharyngeal cancers treated by VMAT

J. Mohan Mathew 1 , N. Vijayaraghavan 2 , A. Mukherji 3 , M. Muthukarthikeyan 4 , G.K. Nair 5 , A. Menon 6 , K. Sriharsha 7

1 Regional Cancer Centre, Radiation Oncology, Thiruvananthapuram, India; 2 Madras Medical College, Medical Oncology, Chennai, India; 3 Tata Memorial Centre, Radiation Oncology, Varanasi, India; 4 JIPMER, Radiation Oncology, Puducherry, India; 5 Government Medical College, Thiruvananthapuram, Radiation Oncology, Thiruvananthapuram, India; 6 Regional Cancer Centre, Thiruvananthapur, Medical Oncology, Thiruvananthapuram, India; 7 The Christie, Clinical Oncology, Manchester, United Kingdom Purpose or Objective To assess xerostomia in patients diagnosed with laryngo- pharyngeal- cancers treated with radical radiotherapy ± chemotherapy and correlate it with the mean submandibular gland dose. Materials and Methods 33 patients diagnosed with laryngo- pharyngeal cancers were prospectively assessed with a questionnaire for xerostomia prior to start and at 3 and 6 months post treatment. The questionnaire addressed dryness in the stimulated and unstimulated setting (1). Submandibular gland was contoured but constraints were not given. Patients were treated with radical radiotherapy ± chemotherapy to a dose of 66, 60 and 54 Gy in 30 fractions to the high, intermediate and low risk PTVs with SIB technique using VMAT. Level 1b was treated depending on the risk of involvement based on the location of primary site and other nodal levels involved. Concurrent chemo was 3 weekly cisplatin 100mg/m2. Continuous variables were analysed using ANOVA. Spearman’s test was used to assess correlation of mean submandibular gland dose with dose to other OARs, xerostomia scores and tumour site. Results 30 Patients were male and 28 were smokers. Mean (SD) age of the population was 60 (8) years. 13 patients had oropharyngeal, 16 had laryngeal and 4 had hypopharyngeal tumours. 27patients had T3/T4 primaries and 85% were node positive. 22 patients received concurrent chemo. The mean submandibular gland dose correlated well with the mean doses to oral cavity and parotid gland (p<0.01, r=0.69 and p<0.01, r=0.75 respectively). Tumour site correlated with the submandibular gland dose (p<0.05, r=-0.57) with mean (SD)dose of 52(14.4) Gy for laryngeal, 64 (8.4) Gy for oropharyngeal and 63 (5.1) Gy for hypopharyngeal tumours which were well in excess of the recommended constraints of D mean < 39 Gy. Median xerostomia scores were 0 (5-0), 25(50-3) and 14(41-0) at baseline and at 3 and 6 months after treatment, and this